Aktienanalyse zu Seres Therapeutics Inc (MCRB)MCRBSeres Therapeutics Inc

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Seres Therapeutics Inc is a good buy right now due to its current price of $1.97, which is significantly lower than its 52-week high of $29.98, indicating substantial upside potential. The forward P/E ratio stands at 10.82, suggesting that the stock is undervalued relative to its future earnings potential. Additionally, the recent positive earnings report showed a net income of $4.6 million for Q2, a turnaround from a loss of $19.9 million in the same quarter last year, which reflects improving financial performance.

9 analysts cover MCRB: 7 rate it Buy, 2 Hold and 0 Sell. The average price target is 22.00.